Last updated: September 7, 2026
Antihemophilic factor (human), also called plasma-derived factor VIII or human coagulation factor VIII, is a mature biologic category used to prevent and treat bleeding in hemophilia A and, in some products, von Willebrand disease. The market is stable in absolute clinical demand but has lost share to recombinant and extended-half-life factor VIII products. Its financial profile depends on plasma supply, fractionation capacity, hospital and specialty-pharmacy contracts, and bundled economics with von Willebrand factor products.
The category has limited remaining value from core molecule patents. Commercial protection now rests primarily on manufacturing know-how, plasma collection networks, regulatory approvals, product-specific formulations, supply reliability, and physician familiarity.
What products contain antihemophilic factor (human)?
The principal U.S. products are plasma-derived factor VIII concentrates. Several combine factor VIII with von Willebrand factor.
| Product |
Company |
Product type |
Primary U.S. use |
Commercial position |
| Humate-P |
CSL Behring |
Factor VIII and von Willebrand factor complex |
Hemophilia A and von Willebrand disease |
Established specialty product |
| Alphanate |
Grifols |
Factor VIII and von Willebrand factor complex |
Hemophilia A and von Willebrand disease |
Established plasma-derived product |
| Koate-DVI |
Kedrion Biopharma |
Human factor VIII |
Hemophilia A |
Niche and contract-driven |
| Wilate |
Octapharma |
Factor VIII and von Willebrand factor complex |
Hemophilia A and von Willebrand disease |
Dual-indication product |
| Hemofil M |
Formerly Baxter/Baxalta, now associated with Takeda’s legacy portfolio |
Human factor VIII |
Hemophilia A |
U.S. commercial availability has declined or been discontinued in certain periods |
| Monoclate-P |
CSL Behring legacy product |
Human factor VIII |
Hemophilia A |
Limited or discontinued commercial relevance in the U.S. |
The product class differs from recombinant factor VIII because the active protein is derived from pooled human plasma. The products contain naturally occurring molecular variants and may include von Willebrand factor, depending on the formulation and manufacturing process.
The FDA product labels remain the principal sources for approved indications, dosing, contraindications, viral inactivation processes, and administration requirements (FDA, n.d.-a; FDA, n.d.-b; FDA, n.d.-c).
How large is the antihemophilic factor human market?
No major public company separately reports revenue for “antihemophilic factor (human)” as a standalone category. Reported financials usually combine plasma-derived factor VIII with von Willebrand factor, immunoglobulins, albumin, recombinant products, or broader specialty medicines.
The commercial market is therefore best assessed through demand and product-mix indicators:
| Market driver |
Effect on plasma-derived factor VIII |
| Rising diagnosis and treatment access in emerging markets |
Supports unit growth |
| Greater use of recombinant and extended-half-life factor VIII |
Reduces share in developed markets |
| Gene therapy adoption |
Creates long-term substitution risk |
| Plasma collection constraints |
Raises cost and limits supply |
| Hemophilia prophylaxis |
Supports recurring demand |
| Von Willebrand disease treatment |
Expands demand for combined factor VIII/von Willebrand products |
| Hospital and specialty-pharmacy tenders |
Compresses price |
| Home infusion and specialty distribution |
Supports recurring product utilization |
The global hemophilia treatment market is expanding, but plasma-derived factor VIII is not capturing the full category growth. The strongest growth is in long-acting recombinant factor VIII, non-factor therapies, and gene therapy. Plasma-derived products retain demand where price, availability, established safety data, or von Willebrand disease labeling is important.
What is the financial trajectory of plasma-derived factor VIII?
The financial trajectory is mature to declining in developed markets and selectively growing in underpenetrated markets.
Developed-market trajectory
In the United States, Western Europe, Japan, and other high-income markets, plasma-derived factor VIII faces structural share loss from:
- Recombinant standard-half-life factor VIII.
- Extended-half-life products such as Eloctate, Adynovate, Esperoct, and Altuviiio.
- Emicizumab, a non-factor prophylaxis product for hemophilia A.
- Gene therapies such as Hemgenix and Roctavian, where patients and payers accept the treatment profile.
- Greater use of individualized prophylaxis and pharmacokinetic dosing.
The decline is gradual rather than immediate. Patients with established treatment regimens may remain on plasma-derived products for years. Humate-P, Alphanate, and Wilate also benefit from von Willebrand disease indications, which are less directly exposed to hemophilia-specific alternatives.
Emerging-market trajectory
Demand can increase in countries with low per-capita factor use, improved diagnosis, national hemophilia programs, and expanded reimbursement. These markets are highly price-sensitive and often rely on public tenders. Volume growth does not necessarily translate into equivalent revenue growth because tender pricing is aggressive.
Margin trajectory
Manufacturing economics remain difficult. Plasma-derived factor VIII requires:
- Large-scale plasma collection.
- Screening and testing of donor plasma.
- Fractionation and purification.
- Viral inactivation and removal.
- Batch testing and release.
- Cold-chain or controlled distribution.
- Long-term pharmacovigilance.
The cost of plasma is a major input. Plasma collection costs increased materially during and after the COVID-19 period, creating pressure across plasma-derived therapies. Manufacturers with owned collection centers and integrated fractionation generally have stronger supply control than companies dependent on external plasma procurement.
How does antihemophilic factor human compare with recombinant factor VIII?
Recombinant factor VIII generally has stronger commercial momentum in developed markets, while plasma-derived products retain advantages in selected indications and markets.
| Attribute |
Plasma-derived factor VIII |
Recombinant factor VIII |
| Source |
Human donor plasma |
Recombinant cell culture |
| Viral-risk perception |
Controlled through screening and inactivation, but source is plasma |
No human plasma required for active ingredient |
| Product complexity |
May include factor VIII and von Willebrand factor |
Usually factor VIII only |
| Patent status |
Core patents generally expired |
Some product and formulation patents remain or recently expired |
| Manufacturing barrier |
High due to plasma network and fractionation |
High due to cell culture and purification |
| Market growth |
Mature or declining in developed markets |
More favorable for extended-half-life products |
| Von Willebrand disease utility |
Important for combined products |
Limited unless separately formulated |
| Biosimilar exposure |
No substantial U.S. biosimilar competition as of mid-2024 |
Emerging but still limited |
| Pricing |
Tender and contract pressure |
Premium pricing for convenience and duration |
Humate-P, Alphanate, and Wilate have a competitive advantage when treatment requires both factor VIII and von Willebrand factor. Recombinant factor VIII has a stronger position when physicians and payers prioritize plasma-free production, longer half-life, or established prophylaxis protocols.
What patents protect antihemophilic factor human products?
Core factor VIII composition and use patents are generally expired for legacy plasma-derived products. The commercial patent estate is therefore weaker than the regulatory and manufacturing barriers.
Potentially relevant protection can include:
- Purification and fractionation methods.
- Viral inactivation processes.
- Stabilized formulations.
- Lyophilized dosage forms.
- Reconstitution systems.
- Containers and delivery devices.
- Manufacturing controls.
- Combination products containing factor VIII and von Willebrand factor.
- Specific methods of treating bleeding disorders.
A product’s patent status cannot be inferred from the generic name alone. Patents may cover a branded formulation or manufacturing process rather than the active factor VIII protein.
What is the Orange Book status of antihemophilic factor human?
The Orange Book is not the primary patent reference for biologics. Plasma-derived factor VIII products were generally licensed under biologics frameworks, and their current patent and exclusivity analysis is better conducted through FDA biologics records, product labels, the Purple Book, and patent databases.
The practical consequences are:
- There is no conventional ANDA-based generic pathway for these biologics.
- A Paragraph IV challenge is generally not the relevant mechanism.
- A follow-on biologic would use the Public Health Service Act section 351(k) biosimilar pathway.
- Patent disputes would involve the biologic patent-disclosure and litigation framework rather than the traditional small-molecule ANDA framework.
Legacy products approved before the modern biologics exclusivity system do not receive a new 12-year reference-product exclusivity period merely because they remain marketed. Product-specific regulatory exclusivity must be determined from the original approval history and applicable transitional rules.
Are there Paragraph IV challenges or biosimilar threats?
There is no conventional Paragraph IV risk profile for antihemophilic factor (human). A Paragraph IV certification applies to an abbreviated new drug application. A biosimilar applicant would instead seek approval under section 351(k), potentially using the patent-exchange procedures commonly called the “patent dance.”
As of mid-2024, the U.S. market had no widely commercialized biosimilar competitor to the principal plasma-derived factor VIII products. The near-term threat is more likely to come from therapeutic substitution than from a direct biosimilar launch.
The most important substitutes are:
- Emicizumab for prophylaxis.
- Extended-half-life recombinant factor VIII.
- Newer high-sustained-expression factor VIII products.
- Gene therapy for eligible adults.
- Other non-factor hemostatic agents under development.
Biosimilar development is technically difficult because factor VIII is a complex glycoprotein with multiple structural and functional attributes. Plasma-derived products are also difficult to replicate exactly because their composition reflects donor plasma pools and proprietary fractionation processes.
What FDA regulatory status applies to these products?
Antihemophilic factor (human) products are licensed biologics. Their labels define:
- Hemophilia A treatment and prevention.
- Perioperative bleeding control.
- Some von Willebrand disease indications.
- Pediatric use.
- Reconstitution and infusion procedures.
- Thrombosis and inhibitor warnings.
- Plasma sourcing and viral safety controls.
Regulatory risk is concentrated in manufacturing consistency, supply continuity, viral safety, potency, inhibitor formation, and inspection findings. A product may retain FDA approval while having limited or interrupted commercial availability because of manufacturing or supply decisions.
The FDA’s biologics framework also creates a meaningful barrier to entry. A new competitor must demonstrate comparability, clinical performance, viral safety, manufacturing control, and reliable commercial supply.
What litigation and settlement risks affect the category?
The category has lower current patent-litigation risk than newer recombinant factor VIII products. There is no broad, well-established pattern of active Paragraph IV litigation surrounding the principal plasma-derived products.
The more relevant disputes involve:
- Manufacturing and supply contracts.
- Product liability and adverse-event claims.
- Reimbursement and formulary access.
- Plasma sourcing and quality.
- Distribution agreements.
- Regulatory enforcement.
- Contracting conflicts with hospitals and specialty pharmacies.
Settlement agreements involving generic entry are less central because the market does not operate through ordinary ANDA substitution. Any future biosimilar dispute would likely focus on patent validity, infringement, interchangeability, manufacturing comparability, and launch timing.
Which companies control the competitive landscape?
CSL Behring, Grifols, Octapharma, Kedrion Biopharma, and Takeda’s legacy plasma-derived portfolio are the most relevant commercial entities.
| Company |
Relevant capability |
Strategic advantage |
| CSL Behring |
Plasma collection, fractionation, Humate-P |
Scale and global specialty distribution |
| Grifols |
Plasma-derived medicines and collection network |
Vertical integration |
| Octapharma |
Plasma-derived and recombinant factor products |
International manufacturing and portfolio breadth |
| Kedrion |
Plasma-derived coagulation products |
Specialized factor portfolio and contract access |
| Takeda |
Broad hematology and plasma legacy assets |
Established commercial relationships, though legacy product availability varies |
The strongest competitive moat is not a single patent. It is the combined value of plasma access, validated manufacturing, regulatory history, payer contracts, and supply reliability.
What licensing and partnership activity matters?
Licensing is more important for recombinant factor VIII, gene therapy, and non-factor therapies than for legacy plasma-derived factor VIII. Plasma-derived products are typically managed within the manufacturer’s own collection and fractionation infrastructure.
Commercial partnerships can still affect the category through:
- Regional distribution agreements.
- Public-sector tenders.
- Hospital supply contracts.
- Specialty-pharmacy networks.
- Plasma procurement arrangements.
- Co-promotion or territory licensing.
Public disclosures generally do not allocate licensing revenue or operating profit to individual plasma-derived factor VIII brands. The financial value of a product may therefore be material to a business unit while remaining invisible in segment reporting.
What generic launch scenarios exist?
Three scenarios are commercially plausible.
| Scenario |
Timing profile |
Market effect |
| No direct biosimilar launch |
Near term |
Price pressure comes from tenders and substitution |
| Limited biosimilar entry |
Medium term |
Discounts affect hospital and government contracts |
| Therapeutic displacement |
Ongoing |
Recombinant, non-factor, and gene therapies reduce utilization |
A direct biosimilar would face high development and manufacturing costs, uncertain interchangeability, and a fragmented global market. The more probable near-term risk is declining utilization in patients who switch to emicizumab or extended-half-life recombinant products.
How strong is the patent estate for antihemophilic factor human?
The patent estate is weak for the original factor VIII molecule and stronger for manufacturing and commercial execution.
| Protection category |
Relative strength |
| Core factor VIII composition |
Low for legacy products |
| Broad treatment method claims |
Low to moderate |
| Purification and viral inactivation |
Moderate |
| Formulation and stability |
Moderate |
| Device and reconstitution system |
Moderate |
| Plasma collection network |
High operational barrier |
| Regulatory manufacturing history |
High practical barrier |
| Brand and physician familiarity |
Moderate commercial barrier |
| Direct biosimilar competition |
Currently limited |
Patent expiry therefore does not imply immediate generic substitution. The category’s defensibility is based more on operational complexity than on exclusivity rights.
What is the investment outlook for antihemophilic factor human?
The category is a cash-generative but mature asset class. Its investment profile has four defining characteristics:
- Recurring demand from a chronic genetic disease.
- Declining share in developed markets.
- Supply-chain and plasma-cost exposure.
- Strategic value from combined factor VIII and von Willebrand factor indications.
Revenue is likely to remain resilient for established brands with reliable supply and strong payer access. Volume growth is more likely in emerging markets than in the United States or Western Europe. Margin expansion depends on plasma-cost control, plant utilization, procurement, and the ability to protect premium indications.
The largest long-term risk is not patent expiry. It is treatment migration toward non-factor prophylaxis, extended-half-life recombinant products, and gene therapy.
Key Takeaways
- Antihemophilic factor (human) is a mature plasma-derived factor VIII category.
- Humate-P, Alphanate, Koate-DVI, and Wilate are the principal relevant products in the U.S. market.
- Core molecule patents for legacy products are generally expired or commercially weak.
- Manufacturing, plasma access, regulatory history, and supply reliability are the main barriers to entry.
- Paragraph IV litigation is generally not the relevant competitive mechanism.
- Direct biosimilar competition remained limited as of mid-2024.
- The main commercial threat is substitution by emicizumab, extended-half-life recombinant factor VIII, and gene therapy.
- Combined factor VIII and von Willebrand factor indications support the financial resilience of products such as Humate-P, Alphanate, and Wilate.
- Public companies generally do not disclose standalone revenue for individual plasma-derived factor VIII brands.
- The category is likely to remain strategically relevant but lose share in developed markets over time.
FAQs
Is antihemophilic factor (human) the same as factor VIII?
Yes. Antihemophilic factor (human) is plasma-derived human coagulation factor VIII used to replace deficient factor VIII in hemophilia A.
Is Humate-P a recombinant factor VIII product?
No. Humate-P is derived from human plasma and contains factor VIII together with von Willebrand factor.
Can a generic drug replace plasma-derived factor VIII?
Not through the standard ANDA pathway. A competing biologic would generally require a biosimilar or other biologics approval pathway.
Which product has the strongest protection in von Willebrand disease?
Products containing both factor VIII and von Willebrand factor, including Humate-P, Alphanate, and Wilate, have the clearest positioning for von Willebrand disease treatment, subject to their individual FDA labels.
Will gene therapy eliminate demand for plasma-derived factor VIII?
No. Gene therapy may reduce demand among eligible patients, but contraindications, durability questions, access, reimbursement, patient preference, and treatment eligibility will preserve demand for factor replacement products.
References
- U.S. Food and Drug Administration. (n.d.-a). Humate-P prescribing information.
- U.S. Food and Drug Administration. (n.d.-b). Alphanate prescribing information.
- U.S. Food and Drug Administration. (n.d.-c). Koate-DVI prescribing information.
- U.S. Food and Drug Administration. (n.d.-d). Wilate prescribing information.
- U.S. Food and Drug Administration. (n.d.-e). Purple Book: Database of licensed biological products.
- World Federation of Hemophilia. (2023). Guidelines for the management of hemophilia (3rd ed.).
- Centers for Disease Control and Prevention. (n.d.). Hemophilia treatment and factor replacement therapy.
- CSL Limited. (2024). Annual report 2024.
- Grifols, S.A. (2024). Annual report 2024.
